Opdivo in Head and Neck Cancer: Results from the CheckMate 141 Trial

At the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, Dr. Robert L. Ferris from the University of Pittsburgh presented the results of the CheckMate 141 Phase 3 clinical trial. This study investigated the efficacy of Opdivo (Nivolumab) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who had progressed on platinum-based chemotherapy.

Study Design: CheckMate 141 Trial

The trial randomized 361 patients in a 2:1 ratio:

1. Opdivo Group (N=240): Nivolumab 3 mg/kg every two weeks.
2. Investigator’s Choice Group (N=121): Standard chemotherapy (Methotrexate, Docetaxel, or Cetuximab).

Key Survival Results

The trial demonstrated a significant survival benefit for patients receiving Opdivo:

• One-Year Survival Rate: 36.0% for the Opdivo group vs. 16.6% for the investigator's choice group—effectively doubling the survival rate at one year.
• Median Overall Survival: 7.5 months for Opdivo vs. 5.1 months for standard therapy.

The benefit of Opdivo was observed across different PD-L1 expression levels, though patients with higher PD-L1 expression showed even greater survival improvements.

Safety and Tolerability

Opdivo also proved to be better tolerated than standard chemotherapy:

• Adverse Event Rate: 58.9% in the Opdivo group vs. 77.5% in the investigator's choice group.
• Quality of Life: Patients in the Opdivo group reported stable or improved physical, social, and emotional functioning, whereas those in the chemotherapy group experienced declines.

Conclusion

The CheckMate 141 trial established Opdivo as a new standard of care for patients with platinum-refractory recurrent or metastatic head and neck cancer, offering superior survival and better quality of life compared to conventional chemotherapy.

Source: ASCO 2016 - CheckMate 141 Abstract #6009

#HeadAndNeckCancer #SCCHN #Opdivo #Nivolumab #CheckMate141 #ASCO2016 #Immunotherapy

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5